Thus, alterations in the expression level of the Clu protein, expressed in astrocytes, may serve as a risk factor beyond the GFAP, elucidating the role of Clu in the pathogenesis of AD and contributing to determining whether targeting Clu protein levels is a viable therapeutic option for treating AD. The gene discussed is GFAP; the disease is Alzheimer disease.